Angion Biomedica Corp. and Vifor Pharma announced results from the exploratory Phase 2 GUARD trial of Angion's ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury (CSA-AKI). The trial did not meet its primary endpoint of percentage increase in serum creatinine based upon the area under the curve (AUC).

However, Angion and Vifor Pharma continue to review the data based on the signal demonstrated in the clinically relevant MAKE90 secondary endpoint. The GUARD (Guard Against Renal Damage) trial was designed as a signal-finding trial with a primary objective of determining the feasibility of advancing ANG-3777 into a global Phase 3 trial based upon activity and safety of ANG-3777 in patients at risk for CSA-AKI, as there are no approved therapies for these patients. Topline results from the Phase 2 GUARD trial appear below.

P-values noted were not adjusted for multiple comparisons: The primary endpoint was percentage increase in serum creatinine based upon AUC as measured between 24 hours after the end of surgery through day 6, and indicated there was no significant difference in this short-term endpoint between ANG-3777 and placebo (8.4% vs. 7.3%, p=0.77); The secondary endpoint of MAKE90, which has historically been acceptable to global regulatory agencies as an approvable endpoint, indicated a potential benefit in patients receiving ANG-3777, with fewer patients in the ANG-3777 arm having a MAKE90 event compared to those in the placebo arm. (14.7% vs.

21.5%, adjusted odds ratio of 0.60, p=0.155). MAKE90 is a composite endpoint combining death, initiation of renal replacement therapy, or a greater than 25% decline in Estimated Glomerular Filtration Rate (eGFR) present 90 days after the surgery. The GUARD trial was not powered to demonstrate a statistically significant result on this endpoint; The number of patients who experienced a decline in kidney function as measured by a =25% decrease in eGFR at Day 90 was fewer in the group treated with ANG-3777 (5.6% vs.

16.2%, p=0.012). Other secondary endpoints did not show a clinical benefit, including endpoints on MAKE30 and the incidence of AKI through Day 6. The overall safety profile of ANG-3777 in this trial was consistent with the overall experience in its clinical development program and comparable to placebo. Patients eligible for the GUARD trial were determined to be at risk for acute kidney injury based upon multiple factors, including age, baseline renal function, and complexity of the surgical procedure.

Thirty-one centers in the U.S., Canada, Brazil, and Georgia participated in this exploratory Phase 2 trial. The primary endpoint was mean AUC of the percent increase in serum creatinine above baseline, starting from 24 hours after the end of cardiopulmonary bypass surgery through Day 6. A total of 275 patients were randomized 1:1 to receive four doses of ANG-3777 or placebo = 4 hours after the completion of cardiac surgery. Estimated GFR decline by =25% assessed at 90 days was calculated using the CKD-EPI formula.